-
What Did Valeant Look Like Last Time The Stock Was Under $15?
Tuesday, November 8, 2016 - 12:12pm | 341Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock has tumbled more than 30 percent and hit a new 52-week low of $13.77 before recovering above the $15 per share level. Investors and traders dumped Valeant's stock after the company's third quarter earnings report fell short of Wall...
-
Pot, Meet Kettle: Wells Fargo Says Valeant's Stock Too Risky In Light Of Potential Fraud Charges
Tuesday, November 1, 2016 - 11:48am | 411Read More...Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), saying the new Bloomberg report over potential accounting fraud charges on the company makes the stock further risky for investment. Bloomberg reported that U.S. authorities are investigating potential...
-
Wells Fargo's Analyst Discusses Valeant's 'Apology Tour'
Wednesday, April 27, 2016 - 2:58pm | 346Read More...David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back in February. On Wednesday, he was a guest on CNBC's Halftime Report segment to discuss his views on the company. Maris began by saying that appointing Joe Pappa...
-
Amid Papa's Appointment, Rodman & Renshaw Still Buying Valeant
Tuesday, April 26, 2016 - 8:22am | 297Read More...On April 25, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that the former CEO of Perrigo Company plc Ordinary Shares (NYSE: PRGO), Joseph Papa, would replace the outgoing Mike Pearson as chairman and CEO. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on Valeant...
-
Cramer: What To Know About Perrigo
Friday, April 22, 2016 - 2:07pm | 468Read More...Shares of Perrigo Company plc Ordinary Shares(NYSE: PRGO) fell more than 5 percent after a Wall Street Journal report said its Chief Executive Joseph Papa may move to Valeant Pharmaceuticals Intl Inc (NYSE: VRX), whose shares surged more than 8 percent on the speculation. CNBC's Jim Cramer said if...
-
Why Valeant's New CEO Could Be An Allergan Exec
Monday, March 21, 2016 - 3:41pm | 601Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is trending amid the company's report it plans to move on from current CEO Mike Pearson. On Monday afternoon, analysts Shibani Malhotra and Austin Nelson at Nomura shared their short list of who would make sense to replace him. "In our view...
-
Valeant Bulls Get Some Relief With Three New Independent Directors
Wednesday, March 9, 2016 - 12:59pm | 449Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been in the news a lot lately. Among the potentially unsavory news is the surprise return of CEO Mike Pearson after an extended sick leave, a canceled conference call followed by one-on-one calls to certain bullish analysts, which then raised...
-
Valeant's Calls To Analysts 'Raise Disclosure Questions'
Monday, March 7, 2016 - 3:37pm | 504Read More...Following an extended sick-leave, Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s CEO Mike Pearson has returned to his station at the company's helm. While a call to analysts was cancelled last week, Pearson personally made one-one-one calls to a few analysts, reaching out to those who,...
-
Everything Happening In The M&A Markets Right Now
Tuesday, March 1, 2016 - 12:40pm | 650Read More...In a new report, Deutsche Bank analyst Christopher Mcdonagh named key M&A headlines that could serve as market catalysts this week. Here's a rundown of his full list: Solera Holdings Inc (NYSE: SLH) has extended tender offers for outstanding 6.00 percent Senior Notes due 2021 and 6.125 percent...
-
Long-Time Valeant Bull Jefferies Cuts Price Target 40%
Tuesday, March 1, 2016 - 10:27am | 278Read More...Jefferies' David Steinberg maintained a Buy rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), while lowering the price target from $172 to $106. Steinberg mentioned that CEO Mike Pearson had returned to his position following a severe bout of pneumonia. At the same time, the company withdrew...
-
25 Headlines Moving The Markets This Week
Monday, February 29, 2016 - 1:36pm | 892Read More...In a new report, Deutsche Bank analyst Christopher Mcdonagh named 25 headlines that could serve as market catalysts this week. Here’s a rundown of his full list. 1. Lattice Semiconductor (NASDAQ: LSCC) could be considering a sale after reported interest from a Chinese buyer. 2. Metlife Inc (...
-
Valeant Withdraws Prior Guidance, Announces CEO Mike Pearson Will Return To Work Immediately Following Pneumonia Scare
Monday, February 29, 2016 - 8:35am | 250Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged more than 8 percent early Monday morning after the company issued a business update over the weekend. Valeant confirmed that Michael Pearson will resume his role as CEO, effective immediately. The executive was hospitalized...
-
Valeant Confirms CEO Will Be On Medical Leave Of Absence
Monday, December 28, 2015 - 9:27am | 228Read More...Bloomberg reported on Sunday that Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s CEO Michael Pearson remains hospitalized with a "severe" case of pneumonia. Bloomberg noted that Pearson was discharged by the Morristown Medical Center, a hospital in New Jersey, but the executive is...
-
Valeant CEO On Allegations Against The Company And Future M&A Deals
Wednesday, January 14, 2015 - 9:38am | 361Read More...Even though its bid for Allergan, Inc. (NYSE: AGN) was not successful, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has tasted success in terms of its market-cap. The company’s stock is up 13 percent in last one month and 38 percent in the last three months. However, Valeant is battling a...
